Our Website has changed!
The FOCUS Program
for Onsolis is now part of the FDA
approved TIRF REMS Access program.
On December 28th,
the U.S. Food and Drug Administration (FDA) approved a single,
shared system
Risk Evaluation and Mitigation Strategy (REMS) for the entire class of
transmucosal immediate-release fentanyl (TIRF) prescription medicines. This REMS,
called the TIRF REMS Access
program, includes Onsolis.
You will be directed to the TIRF REMS Access program website to continue.
For further
assistance contact the TIRF REMS Access program at 1-866-822-1483 or
click on www.TIRFREMSaccess.com to access
the website.
Thank you for visiting the FOCUS Program.